early ovarian insufficiency
Conditions
Interventions
control Group: group A was enrolled, they began to take Kuntai capsules on the 5th day of menstruation, 4 capsules (2.0g) three times a day for 12 consecutive weeks
Experimental subjects:After enrollment, oral administration of Kuntai capsule combined with transcutaneous electrical stimulation. 30 groups at a time, 3 times a week, for a total of 12 weeks.
Sponsors
Kunshan First People's Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Meet the POI Western medical diagnostic criteria; (2) Age 20 = age < 40; (3) Signed informed consent and voluntarily participate in this study actively cooperating with follow-up visits; (4) Have not taken hormone drugs within three months before enrollment.
Exclusion criteria
Exclusion criteria: (1) Those who do not meet the inclusion criteria; (2) Patients with primary or secondary amenorrhea caused by congenital dysplasia of reproductive organs congenital gonadal hypoplasia or acquired organic lesions and injuries; (3) Patients with a history of unilateral or bilateral oophorectomy hysterectomy or bilateral fallopian tube surgery in the past; (4) Those who have or are combined with endocrine diseases that affect ovulation; Patients with severe cardiovascular and cerebrovascular hepatic renal or hematopoietic system and other systemic diseases and mental diseases; (5) Those with abnormal karyotype; (6) Those with severe allergies or a history of allergy to traditional Chinese medicine in the past; (7) Those who have participated in other drug clinical trials at the same time and have not yet completed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| luteinizing hormone;ovarian volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| antimullerian hormone;peak syst01ic velocity; | — |
Countries
CHINA
Contacts
Public ContactGuxing
Kunshan First People's Hospital
Outcome results
None listed